Total Payments
$332,625
2024 Payments
$80,548
Companies
36
Transactions
1,168
Medicare Patients
1,211
Medicare Billing
$178,746
Payment Breakdown by Category
Other$221,410 (66.6%)
Travel$47,547 (14.3%)
Consulting$35,855 (10.8%)
Food & Beverage$27,277 (8.2%)
Education$286.61 (0.1%)
Research$250.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $218,660 | 107 | 65.7% |
| Travel and Lodging | $47,547 | 123 | 14.3% |
| Consulting Fee | $35,855 | 10 | 10.8% |
| Food and Beverage | $27,277 | 919 | 8.2% |
| Honoraria | $2,750 | 1 | 0.8% |
| Education | $286.61 | 7 | 0.1% |
| Unspecified | $250.00 | 1 | 0.1% |
Payments by Type
General
$332,375
1,167 transactions
Research
$250.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $113,087 | 220 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59,437 | 71 | $0 (2024) |
| ITI, Inc. | $50,406 | 83 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $37,663 | 56 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $33,994 | 136 | $0 (2024) |
| Axsome Therapeutics, Inc. | $21,055 | 20 | $0 (2024) |
| Ironshore Pharmaceuticals Inc. | $4,944 | 14 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $4,699 | 223 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $1,172 | 39 | $0 (2024) |
| Allergan, Inc. | $1,128 | 68 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $80,548 | 144 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($59,437) |
| 2023 | $46,752 | 100 | ITI, Inc. ($27,774) |
| 2022 | $53,010 | 130 | ITI, Inc. ($22,285) |
| 2021 | $18,299 | 61 | Teva Pharmaceuticals USA, Inc. ($9,973) |
| 2020 | $10,002 | 82 | Teva Pharmaceuticals USA, Inc. ($5,137) |
| 2019 | $75,708 | 267 | Alkermes, Inc. ($54,343) |
| 2018 | $30,069 | 219 | Alkermes, Inc. ($26,673) |
| 2017 | $18,238 | 165 | Alkermes, Inc. ($15,169) |
All Payment Transactions
1,168 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $25.90 | General |
| Category: Neurology | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $25.96 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/14/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Central Nervous System | ||||||
| 11/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $124.93 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/11/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Central Nervous System | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $30.54 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $23.69 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/24/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,260.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Neurology | ||||||
| 10/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,260.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/17/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: Central Nervous System | ||||||
| 10/16/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: ADHD | ||||||
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $25.31 | General |
| Category: Psychiatry/Psychology | ||||||
| 09/11/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 09/11/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 09/11/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 09/11/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $112.63 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 09/11/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $55.61 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 09/11/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 09/06/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: Neurology | ||||||
| 09/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $2.74 | General |
| Category: Neurology | ||||||
| 08/28/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $98.00 | General |
| Category: CNS | ||||||
| 08/16/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,680.00 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Quantitative Testing of Prescriber Knowledge, Attitudes and Behavior about SUBOXONE buprenorphine and naloxone Sublingual Film CIII Safety and Use Information | Indivior Inc. | $250.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 219 | 622 | $71,850 | $34,704 |
| 2022 | 5 | 280 | 736 | $86,225 | $41,983 |
| 2021 | 5 | 366 | 1,038 | $131,525 | $54,126 |
| 2020 | 5 | 346 | 1,052 | $123,800 | $47,932 |
Total Patients
1,211
Total Services
3,448
Medicare Billing
$178,746
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 128 | 424 | $42,400 | $22,966 | 54.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 35 | 132 | $19,800 | $7,712 | 38.9% |
| 90791 | Psychiatric diagnostic evaluation | Facility | 2023 | 19 | 20 | $5,000 | $2,068 | 41.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 15 | 16 | $2,400 | $1,004 | 41.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 22 | 30 | $2,250 | $953.85 | 42.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 159 | 496 | $49,650 | $27,523 | 55.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 37 | 138 | $20,700 | $7,611 | 36.8% |
| 90791 | Psychiatric diagnostic evaluation | Facility | 2022 | 29 | 35 | $8,750 | $4,002 | 45.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 24 | 28 | $4,200 | $1,521 | 36.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 31 | 39 | $2,925 | $1,326 | 45.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 193 | 556 | $55,575 | $24,070 | 43.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 43 | 326 | $48,900 | $18,508 | 37.8% |
| 90791 | Psychiatric diagnostic evaluation | Facility | 2021 | 42 | 51 | $12,750 | $5,990 | 47.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 39 | 53 | $7,950 | $2,945 | 37.0% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2021 | 14 | 14 | $3,500 | $1,561 | 44.6% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 35 | 38 | $2,850 | $1,052 | 36.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 239 | 774 | $77,400 | $30,362 | 39.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 28 | 190 | $28,500 | $11,020 | 38.7% |
| 90791 | Psychiatric diagnostic evaluation | Facility | 2020 | 27 | 31 | $7,750 | $2,975 | 38.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 22 | 27 | $4,050 | $1,586 | 39.2% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2020 | 16 | 16 | $4,000 | $1,197 | 29.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 14 | 14 | $2,100 | $791.99 | 37.7% |
About Dr. William Yetter, MD
Dr. William Yetter, MD is a Psychiatry healthcare provider based in Virginia Beach, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346212230.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Yetter, MD has received a total of $332,625 in payments from pharmaceutical and medical device companies, with $80,548 received in 2024. These payments were reported across 1,168 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($218,660).
As a Medicare-enrolled provider, Yetter has provided services to 1,211 Medicare beneficiaries, totaling 3,448 services with total Medicare billing of $178,746. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Virginia Beach, VA
- Active Since 02/03/2006
- Last Updated 07/29/2013
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1346212230
Products in Payments
- CAPLYTA (Drug) $109,844
- ARISTADA (Drug) $70,837
- Aristada 441 mg (Drug) $35,789
- AUSTEDO (Drug) $32,433
- QELBREE (Drug) $27,707
- Auvelity (Drug) $21,055
- Qelbree (Drug) $9,956
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $4,899
- LATUDA (Drug) $4,070
- VRAYLAR (Drug) $1,448
- SPRAVATO (Drug) $998.51
- Trintellix (Drug) $874.13
- Austedo XR (Drug) $529.37
- Adzenys XR-ODT (Drug) $462.01
- LYBALVI (Drug) $388.64
- REXULTI (Drug) $355.05
- VYVANSE (Drug) $337.51
- INGREZZA (Drug) $326.36
- MYDAYIS (Drug) $278.36
- UZEDY (Drug) $272.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Virginia Beach
Mr. Mark Schreiber, M.d, M.D
Psychiatry — Payments: $30,295
Psychiatry $30,295
Dr. Angelina Espinosa-Guanzon, Md, MD
Psychiatry — Payments: $29,720
Psychiatry $29,720
Mrs. Maria Cenzon, Md, MD
Psychiatry — Payments: $18,877
Psychiatry $18,877
Dr. Heather Rowe, M.d, M.D
Psychiatry — Payments: $16,445
Psychiatry $16,445
Mrs. Elizabeth Kamin, Md, MD
Psychiatry — Payments: $12,321
Psychiatry $12,321
Jolie Hinnenkamp, Pa-C, PA-C
Psychiatry — Payments: $9,327
Psychiatry $9,327